Q-omics provides the consensus-scored ANKRD20A10P profile across patient tissues and cancer cell-line models. ANKRD20A10P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A10P is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ANKRD20A10P RNA expression shows 11,827 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where ANKRD20A10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A10P survival associations across molecular data types. ANKRD20A10P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A10P RNA expression–survival associations across cancer types. High ANKRD20A10P expression shows unfavorable associations in UVM, KIRC, UCEC and LIHC, but favorable associations in LGG and PRAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ANKRD20A10P RNA expression.
This table summarizes ANKRD20A10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A10P shows lower tumor expression in STAD and THCA and higher tumor expression in HNSC, LUSC, LUAD and UCEC. The HNSC box plot shows higher ANKRD20A10P RNA expression in tumor versus normal tissue (log2 FC = +0.426, t-test p = .001).
This table shows molecular features associated with ANKRD20A10P in patient tissues and cancer cell lines. In patient samples, ANKRD20A10P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
